Jason Porter, MD, Eric Vail, MD, and Ana Velázquez Mañana, MD, MSc, present two clinical cases of non-small cell lung cancer (NSCLC), discuss targetable genomic alterations and their approaches to biomarker testing for these patients, and touch on how socioeconomic and racial disparities may effect use of testing.
EP. 1: An Introduction to Biomarker Testing in Non-Small Cell Lung CancerFebruary 21st 2023
Expert panelists are introduced and review common biomarkers in non-small cell lung cancer (NSCLC), followed by a focused discussion on EGFR mutations.
EP. 2: Analyzing the Relationship Between Biomarkers, Testing Rates, and Clinical Characteristics in Non-Small Cell Lung CancerFebruary 21st 2023
Jason Porter, MD, and fellow panelists discuss how expression of NSCLC biomarkers and biomarker testing rates may vary by patients’ clinical characteristics, including tumor histology, stage, race, and sex.
EP. 3: Available Biomarker Testing Modalities for Patients with mNSCLCFebruary 28th 2023
Panelists discuss available biomarker testing methodologies for metastatic NSCLC (mNSCLC), sharing how they optimize molecular profiling in their practices and whether they typically use commercial or in-house tests.
EP. 4: Clinical Experience with Coordinating Biomarker Testing for Patients with mNSCLCFebruary 28th 2023
The panel discusses challenges that clinicians may experience when ordering biomarker testing for patients with mNSCLC, including insurance coverage barriers, timing of testing, insufficient biopsy samples, and inconclusive test results.
EP. 5: Patient Case 1: A 71-year-old Woman with Newly Diagnosed mNSCLCMarch 7th 2023
Eric Vail, MD introduces a patient case, a 71-year-old Asian woman newly diagnosed with mNSCLC, followed by a focused discussion on how the panel would have approached biomarker testing and treatment initiation for the patient.
EP. 6: A Molecular Pathologist’s Insight into Institutional Best Practices for NSCLC Biomarker TestingMarch 7th 2023
Dr Vail shares insight into his ideal institutional approach to biomarker testing for NSCLC, emphasizing the need for local molecular pathology expertise and available in-house biomarker panels.
EP. 8: An Introduction to Three Real-World Analyses of Biomarker Testing Patterns in mNSCLCMarch 14th 2023
Dr Jason Porter introduces three recent retrospective observational studies on use of biomarker testing in mNSCLC, which identified racial and socioeconomic disparities in testing patterns.
EP. 9: Overcoming Disparities in Biomarker Testing Use for mNSCLCMarch 21st 2023
Expert panelists react to the presented data on racial and socioeconomic disparities in biomarker testing for patients with mNSCLC, and align on ways to address and overcome these disparities.
EP. 10: Patient Case 2: mNSCLC with an EGFR Exon 20 InsertionMarch 21st 2023
Dr Ana Velázquez Mañana introduces a second patient case, a 59-year-old Black man diagnosed with mNSCLC and an EGFR exon 20 insertion, and outlines first-line treatment selection for the patient.